NEW YORK, April 14, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding Questcor Pharmaceuticals Inc. (NASDAQ: QCOR), Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), Eli Lilly and Co. (NYSE: LLY), Medtronic Inc. (NYSE: MDT) and Alexion Pharmaceuticals Inc. (NASDAQ: ALXN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1084-100free.
Questcor Pharmaceuticals Inc. Analyst Notes
On April 7, 2014, Questcor Pharmaceuticals Inc. (Questcor) agreed to be acquired by Mallinckrodt PLC (Mallinckrodt) in a deal valued at approximately $5.6 billion, creating a diversified and high-growth specialty pharmaceutical company. The announcement sparked rally in Questcor's stock which gained 18.73% on the day of announcement. Under the terms of the transaction, expected to be completed in Q3 2014, Mallinckrodt would pay a total of $86.10 per share to Questcor, which represents a premium of approximately 27% per share over Questcor's closing price on April 4, 2014. Upon closing, Questcor commercial operations will function as a separate business unit within Mallinckrodt's Specialty Pharmaceuticals segment. Questcor also announced that its Board of Directors has declared a quarterly cash dividend of $0.30 per share, payable on July 8, 2014 to holders of record on July 1, 2014. The full analyst notes on Questcor are available to download free of charge at:
Regeneron Pharmaceuticals Inc. Analyst Notes
On April 4, 2014, Regeneron Pharmaceuticals Inc. (Rgeneron) announced the election of Rober A. Ingram to its Board of Directors. The Company informed that Inagram was nominated by Sanofi which recently reached 20% ownership of Regeneron's total outstanding common stock and Class A stock. In addition, Regeneron announced the retirement of Company's Co-Founder Dr. Eric Shooter from the Board after serving for nearly 26 years. P. Roy Vagelos, M.D., Chairman of the Regeneron Board of Directors, said, "Bob Ingram is an experienced leader with a distinguished career in the pharmaceutical industry. We are extremely pleased to add his expertise, which spans many decades across many senior functions within the industry, to our Board." The full analyst notes on Regeneron are available to download free of charge at:
Eli Lilly and Co. Analyst Notes
On April 9, 2014, Eli Lilly and Co. (Lilly) and T1D Exchange (T1D) jointly announced that they have entered into a research collaboration that will enable both the companies to gain deeper insight into the experience of people with type 1 diabetes, and to identify new ways to improve care. As part of the collaboration, both the companies will jointly work on projects that will bring together Lilly's expertise in type 1 diabetes with T1D Exchange's innovative, patient-centric model that connects a clinic registry of more than 26,000 people with T1D, a clinic network comprised of more than 70 clinics across the U.S., a sample repository that stores patient biosamples and Glu, a patient and caregiver online community for T1D. Under the collaboration, both the companies will engage in multiple projects for an initial five year period. The full analyst notes on Lilly are available to download free of charge at:
Medtronic Inc. Analyst Notes
On April 9, 2014, Medtronic Inc. (Medtronic) announced that its Evera MRI SureScan implantable cardioverter-defibrillator (ICD) System has won CE Mark approval in Europe and becomes the first and only ICD system approved for magnetic resonance imaging (MRI) scans positioned on any region of the body. In line with the approval, the Company also announced the launch of this product in Europe. The Company claims that as many as 63% of ICD patients will need an MRI within 10 years of receiving a device. Commenting on the development, Marshall Stanton, M.D., Vice President and General Manager of the tachycardia business at Medtronic, said, "This means that in addition to having the highest standard in modern ICD treatment, patients implanted with an Evera MRI defibrillator will now have improved access to one of the most important diagnostic tools - the MRI." The full analyst notes on Medtronic are available to download free of charge at:
Alexion Pharmaceuticals Inc. Analyst Notes
On March 10, 2014, Alexion Pharmaceuticals Inc. (Alexion) raised its 2014 financial guidance for revenues and non-GAAP EPS, following an agreement with French government to increase the reimbursement payments for its Soliris. Alexion stated that the agreement also provides reimbursement for shipments of Soliris made prior to January 1, 2014. In Q1 2014, the Company expects to record an additional net product sales of approximately $88 million related to reimbursement for product sales in prior years. For full year 2014, the Company expects net product revenue in the range of $2.15 billion to $2.17 billion, up from previous guidance of $2.00 to $2.02 billion. The non-GAAP diluted EPS is now expected in the range of $4.37 to $4.47 for full year 2014, compared to the previous guidance of $3.70 to $3.80. The full analyst notes on Alexion are available to download free of charge at:
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. This release was produced by first_testproducer last_testproducer, a CFA charter-holder and reviewed by Nidhi Vatsal, a CFA charter-holder. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.
6. Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.
Please visit http://www.analystsreview.com/disclaimer for our full legal disclaimer. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review